Nausea Medicine Global Market Report 2025

The nausea medicine market size has grown strongly in recent years. It will grow from $3.02 billion in 2024 to $3.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth during the historic period can be attributed to the increase in chemotherapy cases, greater awareness of pregnancy-related nausea (NVP), growth in surgical procedures, increased recognition of motion sickness, higher prevalence of chronic gastrointestinal disorders, and the expansion of pediatric formulations.

The nausea medicine market size is expected to see strong growth in the next few years. It will grow to $4.31 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth during the forecast period can be linked to the rising adoption of cancer treatments, regulatory focus on safer ingredients, growth of telehealth and e-prescriptions, expansion of minimally invasive surgeries, and development of hospital infrastructure. Key trends in the forecast period include the integration of digital health solutions, development of targeted therapies, shift toward personalized medicine, adoption of transdermal patches for treatment, and advancements in drug formulations.

The increasing consumption of unhealthy diets is expected to drive the growth of the nausea medicine market in the future. Unhealthy diets typically involve high intake of processed foods, sugars, unhealthy fats, and salt while lacking essential nutrients such as vitamins, minerals, and fiber. The growing preference for processed and fast foods, which are more affordable and convenient than healthier alternatives, is fueling this trend. Consuming such diets often leads to gastrointestinal discomfort, acid reflux, indigestion, and nausea. Nausea medicines, such as antiemetics, help relieve these symptoms by addressing the underlying causes, including motion sickness, gastrointestinal issues, or medication side effects. These medicines work by blocking brain signals that trigger nausea or by soothing the stomach to reduce the urge to vomit. For example, the American Journal of Preventive Medicine reported in April 2025 that over 124,000 deaths in the United States annually are linked to ultra-processed foods. As unhealthy eating habits continue to rise, the demand for nausea medicine is also increasing.

Major companies in the nausea medicine market are focusing on developing innovative solutions, such as medications for chemotherapy-induced nausea. These drugs are specifically designed to prevent or alleviate nausea and vomiting caused by cancer chemotherapy, often by targeting serotonin or neurokinin receptors in the brain. For instance, in January 2023, Glenmark Pharmaceuticals, an India-based pharmaceutical company, launched AKYNZEO I.V., a ready-to-dilute intravenous injection that combines fosnetupitant and palonosetron to prevent chemotherapy-induced nausea and vomiting (CINV). This single-dose intravenous medication offers protection against both the acute and delayed phases of CINV, simplifying treatment and improving patient compliance by reducing the need for multiple antiemetic drugs.

In June 2022, Eagle Pharmaceuticals Inc., a US-based company specializing in injectable products, acquired Acacia Pharma Group plc for an undisclosed amount. The acquisition allows Eagle Pharmaceuticals to expand its acute care and oncology portfolio by adding two FDA-approved products, while also leveraging its experienced sales team to increase market uptake. Acacia Pharma Group, a UK-based pharmaceutical company, develops and commercializes various medicines, including anti-nausea treatments.

Major players in the nausea medicine market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer Aktiengesellschaft, Merck & Co. Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Helsinn Healthcare SA, Mylan N.V., Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, Zydus Lifesciences Limited, Amneal Pharmaceuticals Inc.

North America was the largest region in the nausea medicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nausea medicine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nausea medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Nausea medication is a drug designed to counteract the body's emetic response by targeting specific receptors in the brain or gastrointestinal tract that cause nausea and vomiting. It is used to reduce or prevent nausea and vomiting resulting from conditions such as motion sickness, anesthesia, chemotherapy, gastrointestinal disorders, or pregnancy-related issues.

The main types of nausea medications are antagonists, cannabinoids, and others. Antagonists are substances (typically drugs) that bind to receptors in the body to block or lessen a biological response by preventing the action of other substances, such as hormones or neurotransmitters. These medications are used for various conditions, including oncology, gastroesophageal reflux disease, motion sickness, seasickness, and more. They can be administered through different routes, such as oral, injectable, transdermal, and rectal. These medications are available at retail pharmacies, hospital pharmacies, online pharmacies, and other outlets, catering to various users, including hospitals, home care settings, ambulatory surgical centers, long-term care facilities, and individual consumers.

The nausea medicine market research report is one of a series of new reports that provides nausea medicine market statistics, including nausea medicine industry global market size, regional shares, competitors with a nausea medicine market share, detailed nausea medicine market segments, market trends and opportunities, and any further data you may need to thrive in the nausea medicine industry. This nausea medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nausea medicine market consists of sales of products including dopamine antagonists, ginger supplements, serotonin antagonists, anticholinergics, and antihistamines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.